Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
NUV-422-04 is an open-label Phase 1b/2 dose escalation and expansion study designed to
evaluate the safety and efficacy of NUV-422 in combination with enzalutamide. The study
population is comprised of adults with mCRPC. Patients will self-administer NUV-422 and 160
mg enzalutamide orally in 28-day cycles. Patients will be treated until disease progression,
toxicity, withdrawal of consent, or termination of the study.